The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

H. Stass

BAYER AG

Pharma Research Centre

ICP, 42096 Wuppertal

Germany

[email]@bayer-ag.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • BAYER AG, Pharma Research Centre, ICP, 42096 Wuppertal, Germany. 2005
  • Clinical Pharmacology, Bayer AG, Wuppertal, Germany. 2004
  • Bayer AG, Clinical Pharmacology, Wuppertal and Clin-Pharma Research AG, Germany. 2002
  • Pharma Research Center, Institute of Clinical Pharmacology, Bayer AG, 42096 Wuppertal, Germany. 1998 - 2001

References

  1. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Stass, H., Kubitza, D., Möller, J.G., Delesen, H. Br. J. Clin. Pharmacol (2005) [Pubmed]
  2. Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. Stass, H., Nagelschmitz, J., Moeller, J.G., Delesen, H. Int. J. Clin. Pharmacol. Ther (2004) [Pubmed]
  3. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Stass, H., Kubitza, D., Halabi, A., Delesen, H. Br. J. Clin. Pharmacol (2002) [Pubmed]
  4. Profile of moxifloxacin drug interactions. Stass, H., Kubitza, D. Clin. Infect. Dis. (2001) [Pubmed]
  5. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Stass, H., Kubitza, D., Schühly, U. Clin. Pharmacokinet (2001) [Pubmed]
  6. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Stass, H., Wandel, C., Delesen, H., Möller, J.G. Clin. Pharmacokinet (2001) [Pubmed]
  7. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Stass, H., Kubitza, D. Clin. Pharmacokinet (2001) [Pubmed]
  8. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Stass, H., Böttcher, M.F., Ochmann, K. Clin. Pharmacokinet (2001) [Pubmed]
  9. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Stass, H., Schühly, U., Möller, J.G., Delesen, H. Clin. Pharmacokinet (2001) [Pubmed]
  10. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Stass, H., Kubitza, D. Clin. Pharmacokinet (2001) [Pubmed]
  11. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. Stass, H., Kubitza, D. Clin. Pharmacokinet (2001) [Pubmed]
  12. Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers. Stass, H., Sachse, R. Clin. Pharmacokinet (2001) [Pubmed]
  13. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Stass, H., Dalhoff, A., Kubitza, D., Schühly, U. Antimicrob. Agents Chemother. (1998) [Pubmed]
 
WikiGenes - Universities